Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Ruth M. O’Regan, MD, and Douglas Yee, MD: Results From the I-SPY2 Trial

Posted: Thursday, December 7, 2017

Ruth M. O’Regan, MD, of the University of Wisconsin Carbone Cancer Center, and Douglas Yee, MD, of the Masonic Cancer Center, University of Minnesota, discuss study findings that showed pathologic complete response predicts event-free and distant disease–free survival.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.